Shares of the largest generic drug company in the world, Teva Pharmaceuticals (TEVA 0.12%), are down more than 7.5% in the last 12 months. This drop largely has to do with fears that biosimilars of the multiple sclerosis drug Copaxone, which currently accounts for a fifth of Teva's top line, may enter the market in the next couple of years. But what growth opportunities does the company have in the future, and what moves can it make to boost investor confidence? Analysts David Williamson and Max Macaluso discuss this topic in this segment from the Motley Fool's health-care show Market Checkup.